AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02027259 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral activation (BA)
Description: The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
Study NCT02821936 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Parametric Imaging
Description: 2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
Study NCT04149132 — intervention group
Intervention type: DEVICE
Intervention: pulse photoplethysmography (PPG)
Description: PPG and systolic blood pressure recording will be performed every two hours for three consecutive days. PPG reading will last two minutes and peaks of NO productions will be captured. Day 1 is considered the day of signing the informed consent followed by the first recording. On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients
Study NCT01940575 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SkinPlus-Hyal®
Description: The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
Study NCT01940575 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restylane®
Description: The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
Study NCT03929575 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Rhodiola and Cordyceps
Description: Ingestion of 250 mg of Rhodiola and 225 mg of Cordyceps
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg
Description: 28 days administration of 100 mg daily
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone 30 mg
Description: 14 days administration of 30 mg daily
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin-placebo
Description: 28 days administration once daily
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin-placebo
Description: 28 days administration once daily
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone-placebo
Description: 14 days administration once daily
Study NCT00721552 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisolone-placebo
Description: 14 days administration once daily
Study NCT00633386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
Study NCT04149132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Measurements of nitric oxide (NO) and malondialdehyde (MDA)
Description: On the first PPG recording of the same days i.e. on days 1, 2 and 3 the investigators will collect blood from the patients. NO will be measured in serum samples by the Griess reaction. MDA that is considered an index of oxidant status will be measured in serum samples by the thiobarbiturate assay and analysis by high-performance liquid chromatography (HPLC)
Study NCT00633386 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT02103556 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mineral oil
Description: 4 ml daily (adjusted as needed), for 4 weeks
Study NCT02103556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Olive oil
Description: 4 ml daily (adjusted as needed), for 4 weeks
Study NCT01414075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Tiered, weight-based dosing per schedule specified in the arm.
Study NCT01414075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Iron
Description: Administered per oral dose and schedule specified in the arm.
Study NCT01414075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Iron
Description: Administered per IV dose and schedule specified in the arm.
Study NCT02408458 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MIROMESH®
Study NCT00969202 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery using the Novalis Tx
Description: Five treatments given every other day.
Study NCT02103556 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil
Description: 4 ml daily (adjusted as needed), for 4 weeks
Study NCT02813954 — intervention group
Intervention type: DEVICE
Intervention: Blood Gas Sampling
Description: analyzing amniotic fluid by blood gas device
Study NCT02955199 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothering From the Inside Out (MIO)
Description: Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
Study NCT02568085 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arista
Description: Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
Study NCT02867787 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botox arm
Study NCT02967497 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YQ1
Description: Oral administered powder
Study NCT03541824 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Body Acceptance Program
Description: The Body Acceptance Program is a mixed-gender modification of the eBody Project, an online intervention in which cognitive dissonance principals are used to reduce eating pathology.
Study NCT02793102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olfactory workshop
Description: Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
Study NCT02793102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Somesthesia workshop
Description: Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
Study NCT02793102 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Auditory workshop
Description: Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
Study NCT02533154 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prosicca
Description: Prosicca eyedrops Dosage: on demand Route of administration: topical
Study NCT02533154 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prosicca sine
Description: Prosicca sine eyedrops Dosage: on demand Route of administration: topical
Study NCT02533154 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bacterial culture
Description: bacterial cultures obtained with conjunctival swabs
Study NCT02533154 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bacterial culture
Description: bacterial cultures obtained with conjunctival swabs
Study NCT02738450 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACI-24 low dose
Description: ACI-24 administered as a sterile suspension in PBS via s.c. injection.
Study NCT02738450 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: ACI-24 high dose
Description: ACI-24 administered as a sterile suspension in PBS via s.c. injection.
Study NCT02738450 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a standard PBS sterile solution administrated via s.c. injection.
Study NCT02955199 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parent Education
Description: Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
Study NCT00605306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol maleate / mometasone furoate
Description: Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
Study NCT00605306 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol maleate/mometasone furoate
Description: Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
Study NCT00326196 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention (PCI)
Description: percutaneous coronary stenting with drug eluding stents
Study NCT00326196 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Coronary artery bypass graft (CABG)
Description: coronary bypass
Study NCT00504855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casting using Gortex (waterproof) cast padding materials
Study NCT00504855 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Casting using cotton/cotton-poly cast padding materials
Study NCT02235675 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tack-It Endovascular System
Description: Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
Study NCT03477851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol Hydrochloride
Description: Tramadol i.m. simultaneous with sciatic nerve block
Study NCT03477851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0,9%NaCl i.m. simultaneous with sciatic nerve block
Study NCT02031835 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: BWSTT (3 days a week for maximum of 20 minutes session)
Study NCT03130387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Office Hysteroscope
Description: Diagnosis of C.S niche in patients wit AUB by office hysteroscope
Study NCT00223977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex
Description: 125 mg weekly x 8 weeks
Study NCT00223977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Ferric Gluconate Complex
Description: 250 mg weekly x 4
Study NCT00223977 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Iron
Description: 325 mg ferrous sulfate orally three times daily x 8 weeks
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: 200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: 50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan
Description: 0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinutuximab Beta
Description: 10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dinutuximab Beta
Description: 10mg/m2/d IV (in the vein) on Days 1 to 7 of a 4 week cycle, for 6 cycles or until progression
Study NCT02308527 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cyclophosphamide
Description: 250mg/m2/d IV (in the vein) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
Study NCT03828422 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: imaging
Study NCT01818258 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ZDV+3TC+LPV/r
Study NCT01025349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab, docetaxel, cisplatin
Description: Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.~docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.~cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s repeated 2 times for a total of 40 times (low pulse: 1200 pulses in total)~Other Names:~intermittent theta burst stimulation
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds repeated for 2 times(low pulse: 1200 pulses in total).~Other Names:~continuous burst stimulation
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iTBS+cTBS group
Description: In iTBS+cTBS pattern, continuous cTBS will be followed by intermittent iTBS (low pulse; 1200 pulses in total)
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham theta burst stimulation
Description: In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 1200 pulses in total).~Other Names:~sham theta burst stimulation
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT
Description: The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.~Other Names:~The upper extremity programs virtual cycling training program
Study NCT03350087 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VCT+optimal rTMS group
Description: In VCT+optimal rTMS group, VCT will be combined with optimal rTMS, which has the best outcome in phase 1.
Study NCT03122353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriene and betamethasone suspension
Description: Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
Study NCT03122353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Taclonex
Description: Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
Study NCT03122353 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: vehicle used as placebo
Study NCT03649529 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GPA-TriMAR-T
Description: Patients will undergo leukapheresis to isolate autologous T cells, these T cells will be activated and modified to express GPA-TriMAR in the manufacture facility, and eventually infused back into the body for treatment.
Study NCT02583230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MedLink System
Description: Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.~The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status.
Study NCT03661905 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive therapy
Description: Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Twelve treatment sessions include components to foster cognitive (i.e. thinking) and behavioural changes.
Study NCT03661905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exposure and Response Prevention
Description: Exposure therapy in which individuals confront their fears and discontinue their escape response. Twelve treatment sessions implementing exposure which is prolonged and repeated, requiring clients/patients to engage in a series of exposures to feared stimuli (e.g., contaminants, doubts, intrusive thoughts), and to refrain from engaging in compulsive behaviour until their anxiety subsides.
Study NCT01985490 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: epiretinal membrane and internal limiting membrane removal
Description: fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
Study NCT02342613 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated PTCy-MILs
Description: The activated PTCy-MILs will be infused through standard blood tubing containing a 170-260 micron filter without an additional leukoreduction filter into a central IV site. Each of the bags will be infused at a rate of approximately 10 ml per minute. The IV line will be flushed with normal saline immediately after completion of PTCy-MILs infusion to ensure that all product has been infused into the patient.
Study NCT03970096 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic CD34+-enriched and CD45RA-depleted PBSCs
Description: Given IV
Study NCT03970096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given IV
Study NCT01462175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5503781
Study NCT00481572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Description: continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
Study NCT00481572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasopressin
Description: continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
Study NCT00481572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Description: titrated norepinephrine over a period of 48 hrs
Study NCT00678925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Phosphatidylcholine
Description: 850 mg per day from 18 weeks pregnancy through 90 days postpartum
Study NCT00678925 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn oil placebo
Description: Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
Study NCT02139241 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramosetron
Description: 0.3 mg IV as bolus before induction of general anesthesia
Study NCT02139241 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 2 ml normal saline as bolus before induction of general anesthesia
Study NCT03754660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1237592
Description: Oral inhalation with dry powder inhaler, single dose.